Lung Cancer Diagnosis Using DNA Methylation Signatures

使用 DNA 甲基化特征诊断肺癌

• 批准号: 6674537
• 负责人: ITE A OFFRINGA
• 金额: $ 16.21万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-01 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6674537
• 关键词: DNA methylation; biotechnology; clinical research; diagnosis design /evaluation; genetic markers; genetic techniques; human subject; lung neoplasms; neoplasm /cancer diagnosis; neoplasm /cancer genetics

DESCRIPTION (provided by applicant): CpG island hypermethylation (the abnormal methylation of cytosine in the context of groups of CpG dinucleotides in the promoter regions of genes) is a common mechanism by which tumor suppressor genes are silenced during cancer development. Different cancer types show distinct patterns of DNA hypermethylation. Thus, analysis of sufficient DNA methylation loci in lung cancer samples should yield loci that are commonly methylated in many cancers, as well as loci that are uniquely methylated in lung cancer. The determination of DNA hypermethylation patterns specific for lung cancer would allow accurate diagnosis of the histological subtype of lung cancer, correlation to clinico-pathological data such as response to treatment and survival (leading to the establishment if predictive markers), and finally, in the future, the development of early detection tools through the identification of methylation changes in the serum and sputum of subjects at risk for lung cancer. To date, however, DNA methylation studies of lung cancer have been limited to single gene loci, or small numbers of loci, which are not hypermethylated at a high enough frequency to be of sufficient diagnostic value. For DNA methylation analysis to be applicable to the accurate diagnosis or early detection of lung cancer, a gene or combination of genes with high sensitivity and specificity for the various histological subtypes of lung cancer needs to be identified. Here we propose to screen a panel of 100 genes to identify loci that are hypermethylated in lung cancer or in certain lung cancer subtypes. We will then evaluate individual loci and panels of loci as general lung cancer markers or markers for lung cancer subtypes. Lastly, we will examine the methylation data to identify correlations of methylation patterns with clinico-pathological features and overall survival. The proposed study will yield data that will form the basis for much larger prospective studies to validate the use of the identified methylation markers to study samples (cancer specimens, sputum and serum) from lung cancer patients and subjects at risk for lung cancer, with the goal to develop markers for lung cancer diagnosis, selection of therapy, prediction of outcome, and detection of recurrence.

描述（由申请人提供）：CpG岛超甲基化（基因启动子区域中CpG二核苷酸组背景下胞嘧啶的异常甲基化）是肿瘤抑制基因在癌症发展过程中沉默的常见机制。不同的癌症类型显示出不同的DNA超甲基化模式。因此，在肺癌样品中足够的DNA甲基化基因座的分析应该产生在许多癌症中通常甲基化的基因座，以及在肺癌中独特甲基化的基因座。肺癌特异性DNA甲基化模式的测定将有助于准确诊断肺癌的组织学亚型，并与临床病理学数据（如治疗反应和生存率）相关（导致建立预测标记），最后，在未来，通过识别有肺癌风险的受试者血清和痰中的甲基化变化，开发早期检测工具。然而，迄今为止，肺癌的DNA甲基化研究仅限于单基因位点或少量位点，这些位点的高甲基化频率不够高，无法提供足够的诊断价值。为了使DNA甲基化分析适用于肺癌的准确诊断或早期检测，需要鉴定对肺癌的各种组织学亚型具有高灵敏度和特异性的基因或基因组合。在这里，我们建议筛选一组100个基因，以确定在肺癌或某些肺癌亚型中高甲基化的基因座。然后，我们将评估作为一般肺癌标志物或肺癌亚型标志物的单个基因座和基因座组。最后，我们将检查甲基化数据，以确定甲基化模式与临床病理特征和总生存率的相关性。 该研究将产生数据，这些数据将成为更大规模的前瞻性研究的基础，以验证使用已鉴定的甲基化标志物来研究肺癌患者和肺癌风险受试者的样本（癌症标本，痰液和血清），目的是开发肺癌诊断，治疗选择，结果预测和复发检测的标志物。